Background: Modified median and subgroup-specific gene subtypes by PAM50 and IHC surrogates improved to fair centering are two essential preprocessing methods to assign when Luminal subtypes were grouped together. Using the breast cancer molecular subtypes by PAM50. We evaluated the modified median method, our study consisted of 46% PAM50 subtypes derived from both methods in a subset of Luminal A, 18% Luminal B, 14% HER2-enriched, 15% Nurses' Health Study (NHS) and NHSII participants; correlat-Basal-like, and 8% Normal-like subtypes; 53% of tumor-ed tumor subtypes by PAM50 with IHC surrogates; and adjacent tissues were Normal-like. Women with the Basal-characterized the PAM50 subtype distribution, proliferation like subtype had a higher ra...
PurposeMulti-gene signatures provide biological insight and risk stratification in breast cancer. In...
Multigene assays for molecular subtypes and biomarkers can aid management of early invasive breast c...
Introduction: HER2-enriched subtype has been associated with higher response to neoadjuvant anti-HER...
BACKGROUND: Many methodologies have been used in research to identify the 'intrinsic' subtypes of br...
Background: Many methodologies have been used in research to identify the "intrinsic" subtypes of br...
Abstract PAM50 gene expression subtypes represent a cornerstone in the molecular classification of b...
To date, there is only one standardized assay for identification of the so-called intrinsic molecula...
Altres ajuts: This study was supported by funds from the NCI Breast SPORE Program (P50-CA58223-09A1)...
Purpose: To compare clinical, immunohistochemical (IHC), and gene expression models of prognosis app...
Abstract Background The four intrinsic subtypes of breast cancer, defined by differential expression...
Purpose: PAM50-defined breast cancer intrinsic subtypes and risk-of-relapse (ROR) scores are progno...
Abstract Background PAM50 gene profiling assigns each cancer to a single intrinsic subtype. However,...
In the CherLOB study, intrinsic subtypes, TILs and immune signatures all contribute to the chance of...
Endocrine therapy (ET), associated with CDK 4/6 inhibitors, represents the first choice of treatment...
Gene expression profiling classifies breast cancer into intrinsic subtypes based on the biology of t...
PurposeMulti-gene signatures provide biological insight and risk stratification in breast cancer. In...
Multigene assays for molecular subtypes and biomarkers can aid management of early invasive breast c...
Introduction: HER2-enriched subtype has been associated with higher response to neoadjuvant anti-HER...
BACKGROUND: Many methodologies have been used in research to identify the 'intrinsic' subtypes of br...
Background: Many methodologies have been used in research to identify the "intrinsic" subtypes of br...
Abstract PAM50 gene expression subtypes represent a cornerstone in the molecular classification of b...
To date, there is only one standardized assay for identification of the so-called intrinsic molecula...
Altres ajuts: This study was supported by funds from the NCI Breast SPORE Program (P50-CA58223-09A1)...
Purpose: To compare clinical, immunohistochemical (IHC), and gene expression models of prognosis app...
Abstract Background The four intrinsic subtypes of breast cancer, defined by differential expression...
Purpose: PAM50-defined breast cancer intrinsic subtypes and risk-of-relapse (ROR) scores are progno...
Abstract Background PAM50 gene profiling assigns each cancer to a single intrinsic subtype. However,...
In the CherLOB study, intrinsic subtypes, TILs and immune signatures all contribute to the chance of...
Endocrine therapy (ET), associated with CDK 4/6 inhibitors, represents the first choice of treatment...
Gene expression profiling classifies breast cancer into intrinsic subtypes based on the biology of t...
PurposeMulti-gene signatures provide biological insight and risk stratification in breast cancer. In...
Multigene assays for molecular subtypes and biomarkers can aid management of early invasive breast c...
Introduction: HER2-enriched subtype has been associated with higher response to neoadjuvant anti-HER...